Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07903831
PHASE1

Phase Ia/Ib Trial of SCTA02A Injection in Healthy Adults and Patients With Chronic Hepatitis B

Sponsor: Sinocelltech Ltd.

View on ClinicalTrials.gov

Summary

Study SCTA02A-A101 is designed to assess the safety, tolerability and pharmacokinetics of SCTA02A in healthy volunteers and participants with chronic hepatitis B virus infection. Eligible participants will receive study treatment in this phase 1 dose-escalation study. All treated patients will also undergo a safety follow-up period after last study drug administration.

Official title: A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase Ia/Ib Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of SCTA02A Injection in Healthy Adults and Patients With Chronic Hepatitis B

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2026-10

Completion Date

2027-12

Last Updated

2026-10-29

Healthy Volunteers

Yes

Conditions

Interventions

BIOLOGICAL

SCTA02A

SCTA02A, an investigational monoclonal antibody.

BIOLOGICAL

Placebo

Placebo

Locations (1)

Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, China